Browse EX-10 agreements

IDAHO COPPER CORPORATION

800 W. MAIN ST, STE 1460

BOISE, ID 83702

** **

DIRECTOR AGREEMENT

** **

THIS DIRECTOR AGREEMENT (the “Agreement”) is made effective as of the 2nd day of July, 2026, and is by and between Idaho Copper Corporation, a Nevada corporation and a US public company (hereinafter referred to as the “Company”), and Corey B. Redfield (hereinafter referred to as the “Director”).

WHEREAS, it is essential to the Company to retain and attract as directors the most capable persons available to serve on the board of directors of the Company (the “Board”).

WHEREAS, the Board believes that Director possesses the necessary qualifications and abilities to serve as a director of the Company and desires to appoint the Director to fill an existing vacancy on the Board and to perform the duties of a Director.

WHEREAS the Director desires to be so appointed for such position and to perform the duties required of such position in accordance with the terms and conditions of this Agreement.

NOW, THEREFORE, in consideration for the above recited promises and the mutual promises contained herein, the adequacy and sufficiency of which are hereby acknowledged, the Company and the Director hereby agree as follows:

1. DUTIES.

…

IDAHO COPPER CORPORATION

800 W. MAIN ST, STE 1460

BOISE, ID 83702

** **

DIRECTOR AGREEMENT

** **

THIS DIRECTOR AGREEMENT (the “Agreement”) is made effective as of the 2nd day of July, 2026, and is by and between Idaho Copper Corporation, a Nevada corporation and a US public company (hereinafter referred to as the “Company”), and Dr. John Moeller (hereinafter referred to as the “Director”).

WHEREAS, it is essential to the Company to retain and attract as directors the most capable persons available to serve on the board of directors of the Company (the “Board”).

WHEREAS, the Board believes that Director possesses the necessary qualifications and abilities to serve as a director of the Company and desires to appoint the Director to fill an existing vacancy on the Board and to perform the duties of a Director.

WHEREAS the Director desires to be so appointed for such position and to perform the duties required of such position in accordance with the terms and conditions of this Agreement.

NOW, THEREFORE, in consideration for the above recited promises and the mutual promises contained herein, the adequacy and sufficiency of which are hereby acknowledged, the Company and the Director hereby agree as follows:

1. DUTIES.

…

** **

IDAHO COPPER CORPORATION

800 W. MAIN ST, STE 1460

BOISE, ID 83702

** **

DIRECTOR AGREEMENT

** **

THIS DIRECTOR AGREEMENT (the “Agreement”) is made effective as of the 2nd day of July, 2026, and is by and between Idaho Copper Corporation, a Nevada corporation and a US public company (hereinafter referred to as the “Company”), and David Herskovits (hereinafter referred to as the “Director”).

WHEREAS, it is essential to the Company to retain and attract as directors the most capable persons available to serve on the board of directors of the Company (the “Board”).

WHEREAS, the Board believes that Director possesses the necessary qualifications and abilities to serve as a director of the Company and desires to appoint the Director to fill an existing vacancy on the Board and to perform the duties of a Director.

WHEREAS the Director desires to be so appointed for such position and to perform the duties required of such position in accordance with the terms and conditions of this Agreement.

NOW, THEREFORE, in consideration for the above recited promises and the mutual promises contained herein, the adequacy and sufficiency of which are hereby acknowledged, the Company and the Director hereby agree as follows:

1. DUTIES.

…

IDAHO COPPER CORPORATION

800 W. MAIN ST, STE 1460

BOISE, ID 83702

** **

DIRECTOR AGREEMENT

** **

THIS DIRECTOR AGREEMENT (the “Agreement”) is made effective as of the 2nd day of July, 2026, and is by and between Idaho Copper Corporation, a Nevada corporation and a US public company (hereinafter referred to as the “Company”), and Gil Atzmon (hereinafter referred to as the “Director”).

WHEREAS, it is essential to the Company to retain and attract as directors the most capable persons available to serve on the board of directors of the Company (the “Board”).

WHEREAS, the Board believes that Director possesses the necessary qualifications and abilities to serve as a director of the Company and desires to appoint the Director to fill an existing vacancy on the Board and to perform the duties of a Director.

WHEREAS the Director desires to be so appointed for such position and to perform the duties required of such position in accordance with the terms and conditions of this Agreement.

NOW, THEREFORE, in consideration for the above recited promises and the mutual promises contained herein, the adequacy and sufficiency of which are hereby acknowledged, the Company and the Director hereby agree as follows:

1. DUTIES.

…

Exhibit No. 10.1

AMENDMENT NO. 1

BARNWELL INDUSTRIES INC. TO AMENDED AND RESTATED

2018 EQUITY INCENTIVE PLAN

Section 4.1 Plan Share Limits and Section 4.2 Individual Share Limits, shall be amended and restated in their entirety to read as follows:

4.1 Plan Share Limits. Subject, however, to the provisions of Section 8 of the Plan, a total of 3,080,000 shares of Stock shall be authorized for Awards granted under the Plan. The maximum number of shares of Stock (subject to adjustment under Section 8 of the Plan) which may be the subject of Incentive Stock Options is 3,080,000. Shares of Stock issued pursuant to the Plan may be either authorized but unissued shares or shares held by the Company in its treasury.

4.2 Individual Share Limits. Subject to adjustment as provided in Section 8 of the Plan, the maximum number of shares of Stock that: (i) may be subject to Options that are Incentive Stock Options that are granted to any individual during any calendar year shall not exceed 340,000 shares of Stock; (ii) may be subject Options (other than Incentive Stock Options) and Stock Appreciation Rights that are granted to any individual during any calendar year shall not exceed 340,000 shares of Stock; (iii) may be subject to Restricted Stock Awards and Restricted Stock Unit Awards that are granted to any individual during any calendar year shall not exceed 270,000 shares of Stock and (iv) may be subject to all other Awards, including Awards intended to constitute Qualified Performance Awards, granted to any individual during any calendar year shall not exceed 100,000 shares

…

AMENDED AND RESTATED EMPLOYMENT AGREEMENT

This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) between Theriva Biologics, Inc., a Nevada corporation, (the “Company”), and Steven A. Shallcross (the “Executive”) is effective as of August 10, 2026 (the “Effective Date”) and replaces and supersedes the employment agreement between the Executive and the Company, dated March 3, 2025 (the “Prior Agreement”).

W I T N E S S E T H:

WHEREAS, the Executive has been employed by the Company as its President, Chief Executive Officer and Chief Financial Officer pursuant to the terms of the Prior Agreement;

WHEREAS, the Company desires to continue to employ the Executive as its President, Chief Executive Officer and Chief Financial Officer and the Executive desires to accept such employment, on the terms and conditions set forth in this Agreement; and

WHEREAS, the Company and the Executive have mutually agreed that, as of the Effective Date, this Agreement shall replace the Prior Employment Agreement in its entirety.

NOW, THEREFORE, in consideration of the promises and the mutual covenants and agreements contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound hereby, agree as follows:

1. EMPLOYMENT.

(a) TERMINATION OF PRIOR EMPLOYMENT AGREEMENT. This Agreement replaces the Prior Employment Agreement dated March 3, 2025.

…

AMENDMENT NO. 1
TO THE PROTARA THERAPEUTICS, INC.
2024 EQUITY INCENTIVE PLAN, AS AMENDED

THIS AMENDMENT NO. 1 to the Protara Therapeutics, Inc. 2024 Equity Incentive Plan, as Amended (the “Plan”) is approved by the Board of Directors of Protara Therapeutics, Inc., a corporation organized under the laws of the State of Delaware (the “Company”) as of April 8, 2026 to be effective as set forth herein.

WHEREAS, the Company previously established the Plan; and

WHEREAS, the Company now desires to amend the Plan to increase (i) the aggregate number of shares of Company common stock (“Stock”) available for issuance under the Plan and (ii) the number of shares of Stock issued pursuant to incentive options under the Plan (collectively, the “Proposed Amendments”).

NOW, THEREFORE, the Plan is hereby amended, as follows:

Section 4.1(a) of the Plan is hereby amended by deleting the present section in its entirety and substituting the following in lieu thereof:

(a) Limitation. At no time shall the number of shares of Stock issued pursuant to or subject to outstanding Awards granted under the Plan (including pursuant to Incentive Options), nor the number of shares of Stock issued pursuant to Incentive Options, exceed 9,300,000 shares of Stock. Shares of Stock subject to awards that are assumed, converted or substituted under the Plan as a result of the Company’s acquisition of another company (including by way of merger, combination or similar transaction) will not count against the number of shares that may be granted under the Plan.

…

​

​

CERTAIN PERSONALLY IDENTIFIABLE INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT PURSUANT TO ITEM 601(a)(6) OF REGULATION S-K. THE OMITTED INFORMATION IS INDICATED BY “[***].”

​

STRICTLY PRIVATE & CONFIDENTIAL

ADDRESSEE ONLY

​

Áine Miller

[***]

​

Re: Special Employer Pension Contribution

18 June 2026

Dear Áine,

I write to confirm that Theravance Biopharma Ireland Limited will make a once off Employer Special Contribution to the Theravance Biopharma Ireland Ltd Pension Scheme in the amount of $250,000 USD to be converted to Euros on contribution date. The employer special contribution will be invested in the Pension fund in accordance with your current investment instructions.

The once off employer contribution will be paid by Theravance Biopharma directly to the pension plan or within 30 days following your termination date of 15 November 2026.

​

Yours sincerely,	​
/s/ Rick E Winningham	​
Rick E Winningham	​

​

---

​

​

CERTAIN PERSONALLY IDENTIFIABLE INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT PURSUANT TO ITEM 601(a)(6) OF REGULATION S-K. THE OMITTED INFORMATION IS INDICATED BY “[***].”

​

STRICTLY PRIVATE & CONFIDENTIAL

ADDRESSEE ONLY

​

Áine Miller

[***]

​

18 June 2026

​

Dear Áine,

​

Further to my letter dated 13 March 2026, I now wish to confirm the severance terms on offer to you and the conditions for acceptance of same.

​

This Letter

​

This Letter is sent to you on a without prejudice basis and without admission of liability on the part of Theravance Biopharma Ireland Limited (“the Company”). However, once it is accepted by you, it will serve as a compromise and settlement of all claims and demands (if any) made or which may be made by you, arising from your employment and termination of employment with the Company.

​

For the purpose of this Letter, “Group” means the Company and any Group Company. “Group Company” means any undertaking which for the time being is a subsidiary undertaking or joint venture of the Company, a holding undertaking of which the Company is a subsidiary undertaking, or a subsidiary undertaking or joint venture of such holding undertaking, or an undertaking in which any of the foregoing has a participating interest (the terms “undertaking”, “subsidiary undertaking”  and “holding undertaking” each having the meaning given to it in section 275 of the Companies Act 2014, and the terms “joint venture” and “participating interest” each having the meaning given to it in Schedule 4A to that Act).

​

…

August 6, 2026

Re: Board of Directors of ClearSign Technologies Corporation - Offer Letter

Dear Mr. Larry M. Saddler:

On behalf of ClearSign Technologies Corporation (the “Company,” “ClearSign,” “we,” “our” or “us”) and our Board of Directors (“Board”), I am pleased to offer you a position as a member of our Board. We look forward to working with you on the Board. Should you choose to accept this position as a member of the Board, including service as a member of any committees of the Board, as may be determined by the Board at a later time, this letter shall constitute an agreement (the “Agreement”) between you and the Company and contains all the terms and conditions relating to the services to be provided.

1.       Term. This Agreement shall be through the date of the next annual shareholders’ meeting expected in early June 2027 and commencing on the date you and the Company execute this Agreement although your actual start date can be mutually agreed to be on that date, or a later date. The position shall be up for re-election each year at the annual shareholders’ meeting and upon re-election, the terms and provisions of this Agreement shall remain in full force and effect. You also agree to resign from the Board of Directors if requested by a majority of the then-sitting members of the Board. This Agreement shall be in effect as long as you are a director on the Board.

…

Office Lease

METRO CENTERMETRO CENTER TOWER 950 TOWER LANE

FOSTER CITY, CALIFORNIA

Between

HUDSON METRO CENTER, LLC, a Delaware limited liability company

as Landlord,

and

SAGIMET BIOSCIENCES INC., a Delaware corporation

as Tenant

---

OFFICE LEASE

This Office Lease (this “Lease”), dated as of the date set forth in Section 1.1, is made by and between HUDSON METRO CENTER, LLC, a Delaware limited liability company (“Landlord”), and SAGIMET BIOSCIENCES INC., a Delaware corporation (“Tenant”). The following exhibits are incorporated herein and made a part hereof: Exhibit A(Outline of Premises); Exhibit B(Work Letter); Exhibit C(Form of Confirmation Letter); Exhibit D(Rules and Regulations); Exhibit E(Judicial Reference) and; Exhibit F(Additional Provisions).

1

BASIC LEASE INFORMATION

1.1	Date:	May 28, 2026
1.2	Premises.

…

Exhibit 10.2 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. Research Collaboration and License Agreement This research collaboration and license agreement (“Agreement”) is entered into with effect as of the Effective Date (as defined below) by and between F. Hoffmann-La Roche Ltd with an office and place of business at Grenzacherstrasse 124, 4070 Basel, Switzerland (“FHLR”) and Hoffmann-La Roche Inc. with an office and place of business at 150 Clove Road, Suite 8, Little Falls, New Jersey 07424, U.S.A. (“HLR”; FHLR and HLR collectively referred to as “Roche”), on the one hand, and C4 Therapeutics, Inc. with an office and place of business at 490 Arsenal Way, Suite 120, Watertown, MA 02472 (“C4T”), on the other hand.

---

---

…